# Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma

> **NCT05221385** · PHASE1 · TERMINATED · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 58 (actual)

## Conditions studied

- Solid Tumor
- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Gentulizumab

## Key facts

- **NCT ID:** NCT05221385
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-12
- **Primary completion:** 2023-05-30
- **Final completion:** 2023-10-27
- **Target enrollment:** 58 (ACTUAL)
- **Why stopped:** Due to changes in the sponsor's research strategy
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05221385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05221385, "Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05221385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*